Publication date: September 2026 Source: ESMO Gastrointestinal Oncology, Volume 13, Part B Author(s): A. Ooki, K. Shimozaki, S. Fukuoka, S. Udagawa, K. Yoshino, K. Yoshikawa, T. Wakatsuki, M. Ogura, E. Shinozaki, K. Chin, K. Yamaguchi
Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S294981982600083X?dgcid=rss_sd_all
Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S294981982600083X?dgcid=rss_sd_all
“Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.” ESMO Gastrointestinal Oncology.
@article{article44839,
title = {Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S294981982600083X?dgcid=rss_sd_all}
}